Heart & blood pressure · Philadelphia area, PA
Heart and blood pressure studies in Philadelphia area, PA
60 recruiting studies have a site in the Philadelphia area. This page includes nearby cities such as Upland, Bryn Mawr, Wynnewood, Abington.
60 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 2
A Gene Therapy Study of RP-A501 in Male Patients With Danon Disease
Rocket Pharmaceuticals Inc.
- Location
- Philadelphia, PA + 2 other US sites
- Eligibility basics
- Ages 8+ · Men only
- Recruiting
Safety and Effectiveness of Left Bundle Branch Area Pacing Versus Conventional Cardiac Resynchronization Therapy in Heart Failure
Boston Scientific Corporation
- Location
- Philadelphia, PA + 39 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2/Phase 3
A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy
Kardigan, Inc.
- Location
- Philadelphia, PA + 26 other US sites
- Eligibility basics
- Ages 18+
- Recruiting
ELEVATE-HFpEF Clinical Study
Medtronic Cardiac Rhythm and Heart Failure
- Location
- Lancaster, PA + 25 other US sites
- Eligibility basics
- Ages 40+
- Recruiting
A Study of VARIPULSE Catheter in Participants With Persistent Atrial Fibrillation Undergoing Pulmonary Vein and Superior Vena Cava Isolation
Biosense Webster, Inc.
- Location
- Philadelphia, PA + 10 other US sites
- Eligibility basics
- Ages 18–80
- Recruiting
THRIVE- THerapeutic IntravasculaR Ultrasound (TIVUS™) REnal Denervation System Versus Sham for the Adjunctive Treatment of Hypertension
SoniVie Inc.
- Location
- Lancaster, PA + 33 other US sites
- Eligibility basics
- Ages 22–75
- Recruiting
Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation.
Medtronic Cardiovascular
- Location
- Harrisburg, PA + 68 other US sites
- Eligibility basics
- Ages 18+
- Recruiting
Starlight Cardiovascular Lifeline Ductus Arteriosus Stent IDE Study
Starlight Cardiovascular Inc
- Location
- Philadelphia, PA + 7 other US sites
- Eligibility basics
- Up to age 6 mo
- Recruiting
Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure
BrioHealth Solutions, Inc.
- Location
- Philadelphia, PA + 46 other US sites
- Eligibility basics
- Ages 18–100
- Recruiting
Safety and Performance Assessment of the Sphere-9™ Catheter and Affera™ Ablation System for the Treatment of Ventricular Tachycardia (Sphere-9 VT EFS)
Medtronic Cardiac Ablation Solutions
- Location
- Philadelphia, PA + 5 other US sites
- Eligibility basics
- Ages 18–85
- RecruitingPhase 1
A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery Disease
Verve Therapeutics, Inc.
- Location
- Philadelphia, PA + 9 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 2/Phase 3
Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)
Merck Sharp & Dohme LLC
- Location
- Philadelphia, PA + 19 other US sites
- Eligibility basics
- Ages 1 mo–17
- RecruitingPhase 1/Phase 2
ALXN2350 in Adult Participants With BAG3-Associated Dilated Cardiomyopathy
Alexion Pharmaceuticals, Inc.
- Location
- Philadelphia, PA + 6 other US sites
- Eligibility basics
- Ages 18–70
- Recruiting
Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure
Procyrion
- Location
- Abington, PA + 31 other US sites
- Eligibility basics
- Ages 21+
- RecruitingPhase 3
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
Eidos Therapeutics, a BridgeBio company
- Location
- Philadelphia, PA + 39 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 2/Phase 3
Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis: A Randomized, Placebo Controlled Study
Kardigan, Inc.
- Location
- Philadelphia, PA + 46 other US sites
- Eligibility basics
- Ages 50+
- RecruitingPhase 2
A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis
Novartis Pharmaceuticals
- Location
- Philadelphia, PA + 29 other US sites
- Eligibility basics
- Ages 50–80
- Recruiting
Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure
Abbott Medical Devices
- Location
- Abington, PA + 56 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy
Imbria Pharmaceuticals, Inc.
- Location
- Philadelphia, PA + 19 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)
Merck Sharp & Dohme LLC
- Location
- Philadelphia, PA + 8 other US sites
- Eligibility basics
- Ages 1–17
- RecruitingPhase 3
Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction - Coronary Computed Tomography Angiography Trial
Amgen
- Location
- Philadelphia, PA + 5 other US sites
- Eligibility basics
- Ages 35–80
- Recruiting
The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With FMR
Cardiac Dimensions, Inc.
- Location
- Lancaster, PA + 50 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels
NewAmsterdam Pharma
- Location
- Philadelphia, PA
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
Intellia Therapeutics
- Location
- Philadelphia, PA + 36 other US sites
- Eligibility basics
- Ages 18–90
Who these studies look for
Many require a diagnosis or specific lab values such as LDL cholesterol or blood pressure readings, and exclude recent heart events.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.